Research Library

Ziftomenib + Chemotherapy Drives Deep Remission in Frontline AML

Ziftomenib combined with standard 7+3 chemotherapy achieved deep and durable remissions in newly diagnosed NPM1-mutant and KMT2A-rearranged AML. May become new standard of care. Ziftomenib was FDA-approved in November 2025 for relapsed/refractory NPM1-mutant AML.

WHO Warns Cancer Cases Projected to Nearly Double by 2050

The WHO issued an urgent call for action as global cancer cases are projected to nearly double by 2050. Cancer currently claims more than 26,000 lives every day. The report emphasizes the growing physical, emotional, and financial toll and calls for accelerated investment in prevention, screening, and treatment worldwide.

NCCN Updates Bladder Cancer Guidelines with ctDNA MRD Testing

Updated NCCN bladder cancer guidelines incorporate ctDNA MRD testing to guide adjuvant immunotherapy. Phase 3 data showed adjuvant atezolizumab nearly doubled disease-free survival in ctDNA-positive muscle-invasive bladder cancer, establishing ctDNA as an actionable biomarker.

ASCO Updates Breast Cancer Follow-Up Guidelines with Risk-Based Surveillance

ASCO published updated breast cancer follow-up guidelines shifting toward personalized, risk-based surveillance. Key changes include tailored mammography frequency based on individual risk and new guidance limiting routine ctDNA testing to specific clinical scenarios.

New ASCO Guidelines for Thyroid Cancer Treatment

ASCO released new guidelines for thyroid cancer systemic treatment: molecular testing for advanced/aggressive cases; dabrafenib+trametinib+pembro for BRAF-mutant anaplastic thyroid cancer; not all immunotherapy fits every type; targeted agents can reduce surgical intervention; multidisciplinary tumor board decisions recommended.

Scientists Crack Natures Secret for Building Better Cancer Drugs

Researchers at the University of Warwick decoded the natural mechanism bacteria use to manufacture complex cancer-fighting compounds. This could dramatically accelerate development and production of new cancer drugs using bacterial biosynthesis rather than traditional chemical synthesis.

CityU Hong Kong Breakthrough: How Histone Mutations Drive Cancer and How to Target Them

Researchers at CityU Hong Kong led by Prof. Kui Ming Chan published breakthrough studies revealing how histone protein mutations act as key regulators of gene expression that can drive cancer, and identified therapeutic strategies to target these mutations.

SL Science Gamma Delta T-Cell Therapy Eradicates Brain Tumors in Preclinical Study

SL Science announced successful preclinical results for a novel gamma delta T-cell therapy for brain cancer. At the highest dose, the therapy completely eradicated brain tumors by day 26. Gamma delta T cells target cancer without requiring specific antigen matching, making them a promising off-the-shelf option.

FDA Approves Gedatolisib (Revtorpyk) for ER+/HER2- Metastatic Breast Cancer

FDA approved gedatolisib (Revtorpyk), a multi-targeted kinase inhibitor blocking all four PI3K isoforms plus mTORC1/mTORC2, for ER+/HER2- metastatic breast cancer (60-70% of all mBC). Based on Phase 3 VIKTORIA-1 trial led by Dr. Sara Hurvitz at Fred Hutch.

MD Anderson Unveils Major Cancer Research Breakthroughs

MD Anderson shared results across 6 studies: virus-specific T cell therapy for PML brain infection (56.8% response, 61.1% one-year survival); ALLO-316 CAR T for kidney cancer (half of patients saw tumors stop growing or shrink); six-gene signature for colorectal cancer recurrence prediction; KRAS inhibitors for appendix cancer (all 15 patients had reduced tumor markers); immune ecotype mapping in multiple myeloma.

FDA Approves New Targeted Therapy for EGFR-Mutant NSCLC

The FDA has approved a new next-generation EGFR inhibitor for patients with metastatic non-small cell lung cancer carrying exon 20 insertion mutations, offering a new option for a historically hard-to-treat subgroup.

NCCN Guidelines: Non-Small Cell Lung Cancer v.4.2025